Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04978701
Other study ID # NFEC-2021-220
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2021
Est. completion date June 30, 2025

Study information

Verified date November 2021
Source Nanfang Hospital of Southern Medical University
Contact Yin Jia, Master
Phone +86 13802964883
Email jiajiayin@139.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Recent studies have found a close relationship between acute ischemic stroke(AIS) and gut microbiota, but whether the dynamic changes in human microbiome after stroke can predict poor prognosis of stroke remains unclear. Therefore, we planned to explore the predictive value of human microbiome and its metabolites in stroke prognosis through a multicenter cohort study


Description:

This study was designed as a prospective, observational, multicenter cohort study. 2000 patients with AIS will be enrolled continuously through multiple centers. Oral swabs, feces (the day after admission, 1 month, 3 months after the onset of disease) and blood samples (the day after admission, 3 months after the onset of disease) will be collected. After the onset of the disease (1 month, 3 months, 6 months and 12 months), outpatient/telephone follow-up will be conducted to evaluate the neurological function scores of the patients, and the recurrence of stroke and other cardio-cerebrovascular events will be recorded.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date June 30, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Meet the AIS diagnostic criteria; - Age 18-80; - Within 7 days of the onset; - Signing the informed consent, providing relevant medical history and biological specimens. Exclusion Criteria: - mRS > score 2 before onset; - Serious systemic diseases including malignant tumors; - Hematological diseases and autoimmune diseases; - ALT or AST > 2 times the upper limit of normal value or severe liver disease; - Serum creatinine > 1.5 times the upper normal limit or severe nephropathy; - History of alcoholism, drug abuse, and chemical poisoning (e.g. pesticide poisoning); - History of intestinal tumor, irritable bowel syndrome or inflammatory bowel disease or confirmed in hospital; - Antibiotic use within 1 month before admission; - Fece cannot be obtained within 4 days after admission.

Study Design


Locations

Country Name City State
China Department of Neurology, NanFang Hospital, Southern Medical University Guanzhou Guangdong

Sponsors (8)

Lead Sponsor Collaborator
Nanfang Hospital of Southern Medical University Guangdong Yanling Hospital, Huzhou Central Hospital, Zhejiang Province, People's Hospital of Leshan, Sichuan Province, Shenzhen University General Hospital, The First Hospital Of Qiqihar, Zhejiang Greentown Cardiovascular Hospital, Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary modified Rankin Scale An evaluation of neurological deficits 3 months after the onset
Primary National Institute of Health stroke scale An evaluation of neurological deficits 3 months after the onset
Primary Major ischemic events Major ischemic event is defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event. within 3 months
Secondary modified Rankin Scale An evaluation of neurological deficits 6 months after the onset
Secondary National Institute of Health stroke scale An evaluation of neurological deficits 6 months after the onset
Secondary Major ischemic events Major ischemic event is defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event. within 6 months
Secondary modified Rankin Scale An evaluation of neurological deficits 12 months after the onset
Secondary National Institute of Health stroke scale An evaluation of neurological deficits 12 months after the onset
Secondary Major ischemic events Major ischemic event is defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event. within 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3
Completed NCT01021319 - Identification of Stroke Patients ≤ 3 and ≤ 4.5 Hours of Symptom Onset by Fluid Attenuated Inversion Recovery (FLAIR) Imaging and Diffusion Weighted Imaging (DWI)